Modafinil

Eugeroic, Psychostimulant (atypical)

Modafinil

Provigil (Teva/Cephalon); Alertec (Canada); Modavigil (Australia)

Modafinil is a wakefulness-promoting medicine approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as an adjunct to primary treatment), and shift-work sleep disorder. Classified as a eugeroic (from the Greek for "good arousal"), it sits in or adjacent to the psychostimulant class but differs from amphetamines and methylphenidate in both mechanism and clinical profile: it promotes sustained alertness with lower sympathomimetic activation, less euphoria, and substantially lower abuse potential. Modafinil is widely used off-label for cognitive enhancement and fatigue management, generating a large and contentious literature on its effects in non-sleep-deprived healthy individuals.

History

Modafinil was developed in France in the late 1970s by Michel Jouvet and Lafon Laboratories. Jouvet, a neurophysiologist at the University of Lyon whose work on sleep neuroanatomy had identified the pontine structures governing REM sleep, was investigating a series of benzhydryl sulfinyl compounds for wakefulness-promoting activity. Adrafinil, the prodrug of modafinil, was identified first; modafinil (the primary active metabolite) was subsequently isolated and found to be more potent with a cleaner pharmacokinetic profile.^{[citation needed]}

Adrafinil was marketed in France in 1986 under the brand name Olmifon for narcolepsy and age-related hypersomnia. Modafinil itself received French marketing authorization in 1994. Cephalon, Inc. (later acquired by Teva Pharmaceutical Industries in 2011) licensed modafinil for the US market. The FDA approved modafinil (as Provigil) in December 1998 for narcolepsy; subsequent approvals added obstructive sleep apnea (adjunct) and shift-work sleep disorder in 2004.

In 2004, Cephalon submitted a supplemental new drug application for modafinil in pediatric ADHD. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee recommended against approval in 2006, citing one case of Stevens-Johnson syndrome and several cases of serious rash in the pediatric clinical trials. This safety signal, in a population without a life-threatening indication, led the FDA to reject the application and to add a boxed-level warning about serious dermatologic reactions to the adult label.^{[citation needed]}

Armodafinil (Nuvigil), the isolated R-enantiomer, was approved by the FDA in 2007. Its longer half-life relative to racemic modafinil was the basis for marketing differentiation. Generic modafinil became available in the United States in 2012 following patent expiration, substantially reducing cost and increasing accessibility.^{[citation needed]}

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

FDA-approved indications:

• Narcolepsy: Improvement of wakefulness in adults with excessive sleepiness associated with narcolepsy.
• Obstructive sleep apnea (adjunct): Improvement of wakefulness in adults with excessive sleepiness associated with OSA. Modafinil does not treat the underlying airway obstruction; it is an adjunct to CPAP or other primary therapies. The FDA label specifies that it should be used only when CPAP has been tried and is providing adequate ventilation but the patient has residual excessive sleepiness.
• Shift-work sleep disorder: Improvement of wakefulness in adults with excessive sleepiness associated with shift-work disorder (working during the normal sleep period).

Off-label uses (not FDA-approved):

• Fatigue associated with multiple sclerosis, cancer-related fatigue, and HIV/AIDS-related fatigue. Evidence is mixed; some controlled trials show benefit, others do not.^{[citation needed]}
• ADHD in adults (FDA pediatric application rejected due to SJS risk; some evidence of benefit in adults, but this indication is not well-established).^{[citation needed]}
• Cognitive enhancement in healthy non-sleep-deprived individuals (see Experiential perspective below).
• Adjunctive treatment in depression with residual fatigue or sleepiness.^{[citation needed]}
• Fatigue and sleepiness associated with traumatic brain injury.^{[citation needed]}

+ Add a problem

Titration strategies

Narcolepsy and obstructive sleep apnea: 200 mg orally once daily in the morning. Some patients may benefit from 400 mg/day, though evidence for superior efficacy at the higher dose is limited.

Shift-work sleep disorder: 200 mg orally approximately one hour before the start of the work shift.

Hepatic impairment: Reduce dose by 50% (to 100 mg/day) in patients with severe hepatic impairment. Modafinil is extensively hepatically metabolized; clearance is reduced and half-life prolonged in liver disease.

Renal impairment: No dose adjustment needed for mild-to-moderate renal impairment. Severe renal impairment has not been adequately studied; use with caution.^{[citation needed]}

Elderly: Consider lower doses. Clearance may be reduced; the label recommends consideration of 100 mg/day in elderly patients, though this is not a strict requirement.

Pediatric: Not FDA-approved in children. The pediatric ADHD application was rejected due to SJS risk (see History).

+ Add a titration strategy

Effects

Wakefulness promotion. The primary effect is sustained wakefulness and alertness without the subjective "wired" or jittery quality that characterizes higher-dose amphetamine use in many patients. Sleep latency is increased; the Multiple Sleep Latency Test (MSLT) is the standard objective measure in clinical trials.^{[citation needed]}

Cognitive effects. In patients with sleep disorders, modafinil improves attention, executive function, and working memory, consistent with normalizing the cognitive deficits that excessive sleepiness causes. The more contested question is whether modafinil enhances cognition beyond baseline in well-rested healthy individuals. A 2015 systematic review by Battleday and Brem examined 24 studies of modafinil in non-sleep-deprived subjects and concluded that modafinil improved performance on longer, more complex cognitive tasks (particularly executive function, attention, and learning), while effects on simpler tasks were less consistent. The authors noted that methodological heterogeneity limited firm conclusions.

Experiential perspective. Modafinil is widely used off-label as a cognitive enhancer among students, professionals, and shift workers. User reports consistently describe a state of increased focus and reduced fatigue without the physical activation (elevated heart rate, jaw tension, mood elevation) associated with amphetamine-class psychostimulants. The subjective experience is frequently characterized as "quiet alertness" rather than stimulation. This experiential profile contributes to modafinil's reputation as a "cleaner" alternative to traditional psychostimulants for productivity enhancement.

The evidence base for cognitive enhancement in healthy individuals is real but modest. The Battleday and Brem systematic review found benefits in complex cognitive domains, but most studies used single-dose designs in laboratory settings; real-world efficacy for sustained academic or professional performance is not well-characterized in controlled trials. Additionally, there is publication bias: positive results are more likely to be published than null findings, and the magnitude of any cognitive benefit is likely smaller than the most optimistic user reports suggest. Modafinil should not be understood as a reliable cognitive enhancer for all users in all contexts; it is a wakefulness-promoting medicine that may incidentally improve performance in the sleep-deprived and that shows modest, task-dependent benefits in well-rested individuals.

Mood effects. At therapeutic doses, modafinil does not produce the pronounced euphoria associated with amphetamines in most individuals. Some users report improved mood, reduced anxiety, and greater emotional equanimity; others report no subjective mood change. At supratherapeutic doses (600-800 mg), reinforcing effects and subjective "high" have been demonstrated in controlled laboratory settings, establishing that modafinil does carry some abuse potential, though less than Schedule II psychostimulants.Adverse effect incidence from controlled clinical trials (modafinil vs placebo):

Common (>=5% and at least twice placebo rate):

• Headache (34% vs 23%)
• Nausea (11% vs 3%)
• Nervousness (7% vs 3%)
• Rhinitis (7% vs 6%)
• Diarrhea (6% vs 5%)
• Back pain (6% vs 5%)
• Insomnia (5% vs 1%)
• Dizziness (5% vs 4%)
• Dyspepsia (5% vs 4%)

Serious adverse effects:

Dermatologic. Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. The incidence is rare but the consequences are potentially fatal. In pediatric clinical trials, the rash rate was 0.8% (13 of 1,585 children), including one case of possible SJS and one multi-organ hypersensitivity reaction; nearly all cases occurred within the first five weeks of treatment. This dermatologic signal was the primary basis for the FDA's rejection of the pediatric ADHD indication in 2006. In adults, post-marketing reports of SJS/TEN exist but incidence is very low and not precisely quantified.^{[citation needed]} The label recommends discontinuation at the first sign of rash unless the rash is clearly not medicine-related.

Angioedema and anaphylactoid reactions. Rare post-marketing reports of angioedema (face, larynx, tongue), urticaria, and multi-organ hypersensitivity reactions. Discontinue if angioedema occurs.

Psychiatric. Depression, anxiety, mania, hallucinations, suicidal ideation, and psychosis have been reported in post-marketing surveillance. These events occurred primarily in patients with pre-existing psychiatric histories, but the label does not restrict use to patients without psychiatric comorbidity. Use with caution in patients with a history of psychosis, mania, or depression.

Cardiovascular. Not recommended in patients with left ventricular hypertrophy or mitral valve prolapse (the "mitral valve prolapse syndrome" associated with CNS psychostimulants). Modafinil has been associated with palpitations, chest pain, and modest elevations in heart rate and blood pressure. Avoid in patients with recent myocardial infarction or unstable angina.

+ Add an effect

Pharmacokinetics

Absorption

Rapidly absorbed after oral administration. Peak plasma concentration (T_max) occurs at 2-4 hours. Food delays T_max by approximately one hour but does not affect total absorption (AUC). The clinical recommendation to take modafinil in the morning is driven by its long duration of action, not by food-dependent absorption concerns.

Distribution

Modafinil is approximately 60% bound to plasma proteins, primarily albumin. The apparent volume of distribution is approximately 0.9 L/kg, suggesting distribution beyond plasma water into tissues. It crosses the blood-brain barrier; brain concentrations are sufficient for DAT occupancy at therapeutic doses, as demonstrated by PET imaging.

Metabolism

Modafinil is extensively metabolized in the liver. The primary route is amide hydrolysis to modafinil acid (an inactive metabolite), which accounts for approximately 40% of urinary metabolites. CYP3A4 contributes to a secondary oxidative pathway. Notably, modafinil is a moderate inducer of CYP3A4, CYP2B6, and potentially CYP1A2, and a reversible inhibitor of CYP2C19.

The CYP enzyme interactions are clinically important:

CYP3A4 induction. Modafinil induces CYP3A4 at steady state. This reduces plasma levels of CYP3A4 substrates. The most clinically significant consequence is reduced efficacy of hormonal contraceptives (ethinyl estradiol and other estrogen/progestin compounds are CYP3A4 substrates). The FDA label recommends alternative or additional contraception during modafinil therapy and for one month after discontinuation.

CYP2C19 inhibition. Modafinil reversibly inhibits CYP2C19, potentially increasing plasma levels of CYP2C19 substrates (diazepam, phenytoin, omeprazole, propranolol). In CYP2C19 poor metabolizers (2-5% of Caucasian populations, 15-20% of East Asian populations), concurrent modafinil could produce supratherapeutic levels of these substrates.^{[citation needed]}

CYP2C9 inhibition. In vivo cocktail studies found no clinically significant CYP2C9 effect at steady state (AUC ratio 0.97), though the FDA label recommends warfarin monitoring as a precaution.

CYP2D6 relevance. Modafinil does not significantly affect CYP2D6 directly. However, in CYP2D6 poor metabolizers (7-10% of Caucasian populations), metabolism of tricyclic antidepressants becomes heavily dependent on CYP2C19. Modafinil's CYP2C19 inhibition is therefore more clinically significant in these patients: co-prescribed tricyclics may accumulate to supratherapeutic levels.

Elimination

Approximately 80% of the dose is recovered in urine, predominantly as metabolites (modafinil acid and modafinil sulfone). Less than 10% is excreted as unchanged modafinil. The effective elimination half-life is approximately 15 hours. Steady state is reached in 2-4 days of daily dosing. Renal clearance is not a significant elimination pathway for the parent compound.

Pharmacodynamics

Modafinil's pharmacodynamic profile is defined by wakefulness promotion with minimal peripheral sympathomimetic activation at therapeutic doses, distinguishing it from amphetamines.

Dopaminergic. DAT inhibition is the best-established primary mechanism. Volkow et al. (2009) demonstrated using [11C]cocaine and [11C]raclopride PET that modafinil at 200 mg and 400 mg blocked DAT and increased extracellular dopamine in the human nucleus accumbens. The dopamine increase is modest relative to amphetamines, which promote dopamine release in addition to blocking reuptake.

Histaminergic. Modafinil increases histamine release from the tuberomammillary nucleus. Histamine is a key mediator of the ascending arousal system; antihistamines (H1 blockers) produce sedation precisely because they oppose this pathway. Whether modafinil's histamine effect is a direct action or downstream of dopaminergic and GABAergic changes is unresolved.

GABAergic. Modafinil reduces GABA release in multiple brain regions (cortex, hypothalamus, basal ganglia). Reduced GABAergic inhibition of arousal nuclei may contribute to wakefulness promotion and may also explain the anxiogenic effects some patients report.^{[citation needed]}

Glutamatergic. Increased glutamate release has been demonstrated in several brain regions. Enhanced glutamatergic transmission may contribute to the cognitive effects observed in clinical studies.^{[citation needed]}

Noradrenergic. Increased norepinephrine levels in the cortex and hypothalamus have been demonstrated in animal models. The contribution of noradrenergic activation to modafinil's clinical profile is uncertain but likely relevant to attention and arousal.^{[citation needed]}

Absence of significant serotonergic effects. Unlike fenfluramine and other anorectic agents, modafinil does not substantially alter serotonin levels. This may explain the absence of the appetite suppression, mood elevation, and serotonin syndrome risk associated with serotonergic psychostimulants.^{[citation needed]}

Interactions

Hormonal contraceptives (oral contraceptives, patch, ring): Modafinil induces CYP3A4, reducing ethinyl estradiol exposure by approximately 18% at steady state. This is sufficient to reduce contraceptive reliability. Use alternative or additional contraception during modafinil therapy and for one month after discontinuation. This interaction has direct reproductive consequences and should be discussed explicitly with all patients of childbearing potential.

Cyclosporine: CYP3A4 induction by modafinil may reduce cyclosporine blood levels by 50%. One case report documented clinically significant reduction in cyclosporine trough levels after modafinil initiation in a transplant patient. Monitor cyclosporine levels closely if modafinil is started or stopped.^{[citation needed]}

CYP2C19 substrates (diazepam, phenytoin, omeprazole, propranolol): Modafinil inhibits CYP2C19. Co-administration may increase exposure to these substrates. Phenytoin in particular has a narrow therapeutic index; monitor levels if modafinil is added.

Warfarin: Modafinil may inhibit CYP2C9 (minor). Monitor PT/INR more closely when initiating or discontinuing modafinil in patients on stable warfarin therapy.

MAOIs: Use with caution. Modafinil increases catecholamine availability; the combination with MAOIs could theoretically potentiate catecholaminergic effects, though serious interactions are not well-documented.^{[citation needed]}

Other CNS-active medicines: Modafinil is not a strong psychostimulant in the classical sense, but additive wakefulness-promoting effects may mask fatigue signals that serve a physiological protective function. Combining modafinil with other wakefulness-promoting agents or high-dose caffeine is not well-studied.^{[citation needed]}

Triazolam and other CYP3A4-metabolized benzodiazepines: CYP3A4 induction may reduce triazolam exposure by approximately 18%. Consider dose adjustment if concurrent use is necessary.

Monitoring

• Baseline and periodic: blood pressure and heart rate (modest elevations can occur). No routine laboratory monitoring is mandated by the label for patients without comorbidities.
• Rash: counsel patients to report any new rash immediately. The SJS risk, while very low, warrants early recognition and prompt discontinuation.
• Psychiatric symptoms: monitor for new or worsening anxiety, agitation, mania, or psychotic symptoms, particularly in the first weeks of therapy and in patients with psychiatric comorbidity.
• Contraceptive counseling: confirm at each visit that patients of childbearing potential are using reliable non-hormonal or alternative contraception.
• Phenytoin, warfarin, and cyclosporine levels: monitor in patients co-prescribed these medicines when modafinil is initiated, dose-adjusted, or discontinued.

  Patient counseling

Contraception. Modafinil reduces the effectiveness of hormonal contraceptives (birth control pills, patch, ring). Use a non-hormonal method (e.g. IUD, condom) or add a barrier method during modafinil therapy and for one month after stopping. This is among the most clinically consequential interactions and warrants explicit discussion.

Rash. Stop modafinil and contact your clinician immediately if you develop any skin rash. While most rashes during modafinil therapy are benign, Stevens-Johnson syndrome (a rare but serious skin reaction) has been reported. Early discontinuation reduces the risk of progression to a severe reaction.

Driving and operating machinery. Modafinil improves wakefulness but does not eliminate the need for adequate sleep. Do not assume that taking modafinil makes it safe to drive or perform safety-sensitive work during what would otherwise be your sleep period. Judgment about sleepiness is itself impaired by sleep deprivation.

Abuse potential. Modafinil is a Schedule IV controlled substance. While its abuse potential is lower than amphetamines, reinforcing effects have been demonstrated at supratherapeutic doses. Take only as prescribed; do not increase the dose without medical guidance.

Psychiatric history. If you have a history of mania, psychosis, or depression, tell your prescriber before starting modafinil. Report any new mood changes, unusual thoughts, or increased anxiety promptly.

Relevant anecdote

The question of whether modafinil "works" as a cognitive enhancer is, in an instructive way, the wrong question. The 2015 Battleday and Brem systematic review found that modafinil improved performance on complex cognitive tasks in non-sleep-deprived healthy subjects, but the benefits were task-dependent, dose-dependent, and modest in magnitude. Simple tasks (digit span, basic attention) showed inconsistent or no improvement. Complex tasks (Wisconsin Card Sorting Test, sustained attention paradigms, planning tasks) showed more reliable gains.

A subsequent meta-analysis by Roberts et al. (2020) quantified the effect: across 14 studies and 64 effect sizes, modafinil produced a small overall cognitive benefit (standardized mean difference 0.12, p=0.01), with the strongest signal in memory updating (SMD 0.28). For context, methylphenidate showed a somewhat larger pooled effect (SMD 0.21) across more studies, while dextroamphetamine showed no significant overall effect. The authors noted that laboratory paradigms "do not accurately reflect their actual use."

What this suggests is not that modafinil is or isn't a "smart pill," but that the cognitive enhancement question is poorly specified. Modafinil reliably sustains wakefulness and reduces the cognitive costs of fatigue. Whether that constitutes enhancement depends entirely on whether the person taking it was fatigued. For someone who has slept eight hours and is performing a task they find engaging, the evidence for meaningful benefit is thin. For someone running on four hours of sleep performing a cognitively demanding task, the evidence is robust, and the mechanism is obvious: modafinil is doing what it was designed to do.

The cultural framing of modafinil as a "nootropic" sometimes obscures this distinction. It is a medicine for sleepiness that incidentally helps when people are sleepy, which, given the prevalence of insufficient sleep, describes a large share of the population. Whether that incidental benefit constitutes cognitive enhancement or compensatory medicine for a chronically sleep-deprived population is a question about framing, not pharmacology.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Eugeroic, Psychostimulant (atypical)

Common uses

• Narcolepsy★★★★★★★★★★★★★★★—×
• Obstructive Sleep Apnea★★★★★★★★★★★★★★★—×
• Excessive daytime sleepiness in shift-work disorder★★★★★★★★★★★★★★★—×
• Impaired persistent attention★★★★★★★★★★★★★★★—×
• Fatigue★★★★★★★★★★★★★★★—×

+ 1 more use →

Pharmacy

Starting dose

200 mg orally once daily in the morning. For shift-work sleep disorder, 200 mg approximately one hour before the start of the work shift. Doses up to 400 mg/day have been studied; evidence does not consistently demonstrate greater efficacy at 400 mg compared to 200 mg, but some patients may benefit from the higher dose.

Preparations

Tablets: 100 mg, 200 mg (scored). Armodafinil (Nuvigil), the R-enantiomer of modafinil, is available separately as 50 mg, 150 mg, 200 mg, and 250 mg tablets.

US FDA Max

400 mg/day.

Pharmacology

Routes

Oral

Onset

Peak plasma concentration in 2-4 hours after oral administration. Clinically perceptible wakefulness-promoting effects typically begin within 1-2 hours of dosing.^{[citation needed]}

Duration

Effective duration approximately 12-15 hours at the 200 mg dose, consistent with the elimination half-life. A single morning dose generally sustains wakefulness throughout the day without substantially disrupting nighttime sleep onset when taken early.

Half-life

Approximately 15 hours (effective half-life after a single dose). Modafinil is a racemic mixture: the R-enantiomer (armodafinil) has a longer half-life (approximately 15 hours) than the S-enantiomer (approximately 3-4 hours). The R-enantiomer therefore dominates the pharmacologically active plasma concentration in the latter portion of the dosing interval.

Bioavailability

Oral bioavailability is not precisely established in the label but absorption is rapid and essentially complete. Food delays peak plasma concentration by approximately one hour but does not reduce the extent of absorption.

Pregnancy

Not adequately studied in pregnant humans. Animal data (rats, rabbits) showed developmental toxicity at clinically relevant doses, including visceral and skeletal variations. The FDA label does not assign a letter category under the post-2015 labeling rule; the prior category was C (Australia: Category D).^{[citation needed]} A pregnancy registry existed but enrollment data are limited. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Modafinil may reduce the effectiveness of hormonal contraceptives (see Interactions), which has indirect reproductive implications: women of childbearing potential should use alternative or additional contraception during modafinil therapy and for one month after discontinuation.

Legal status

Schedule IV controlled substance in the United States (DEA scheduling effective 1999). Prescription-only in the United Kingdom, European Union, Canada, and Australia. Not scheduled in Japan; available by prescription. In the European Union, the EMA restricted modafinil's approved indication to narcolepsy only in 2011, withdrawing the OSA and shift-work indications after a benefit-risk review.^{[citation needed]} International status varies; in some jurisdictions modafinil is available without prescription. Modafinil was placed in Schedule IV based on evidence of lower abuse potential relative to Schedule II psychostimulants (amphetamines, methylphenidate), though reinforcing effects have been demonstrated in laboratory settings.

Purported mechanism

Modafinil promotes wakefulness through mechanisms that remain incompletely understood. The best-established molecular target is the dopamine transporter (DAT): modafinil binds DAT and inhibits dopamine reuptake, increasing extracellular dopamine concentrations in wakefulness-relevant brain regions including the nucleus accumbens and prefrontal cortex. PET imaging in humans demonstrated that therapeutic doses (200-400 mg) occupy DAT and increase dopamine in the nucleus accumbens, establishing that modafinil is, at the molecular level, a dopamine reuptake inhibitor.

Despite sharing a DAT mechanism with amphetamines and methylphenidate, modafinil's clinical and behavioral profile differs substantially. It produces wakefulness without the pronounced euphoria, sympathomimetic cardiovascular activation, or rebound hypersomnia characteristic of classical psychostimulants at therapeutic doses. The reasons for this divergence are not fully resolved. Proposed contributors include:

Histaminergic activation. Modafinil increases histamine release in the tuberomammillary nucleus, a key node of the ascending arousal system. This effect is not shared by amphetamines and may account for modafinil's selective wakefulness promotion without generalized CNS stimulation. Histamine H1 and H3 receptor pathways appear to be involved, though whether this is a direct or indirect effect remains debated.^{[citation needed]}

Orexin (hypocretin) system engagement. Modafinil activates orexin-producing neurons in the lateral hypothalamus, the same neurons whose loss causes narcolepsy. This activation may be indirect (mediated via reduced GABAergic inhibition of orexin neurons rather than direct receptor binding). Modafinil's efficacy in narcolepsy, a disease defined by orexin deficiency, makes this pathway clinically plausible, though modafinil remains effective in animal models with ablated orexin neurons, indicating that orexin is not its sole mechanism.^{[citation needed]}

Noradrenergic and glutamatergic effects. Modafinil increases norepinephrine release in the cortex and hypothalamus and enhances glutamatergic transmission, while reducing GABA release in several brain regions. These effects collectively shift the excitatory/inhibitory balance toward arousal. Whether they are primary actions or downstream consequences of dopaminergic activation is not established.

The net picture: modafinil acts at least partly as a DAT inhibitor, but its wake-promoting profile likely reflects simultaneous engagement of multiple arousal circuits (dopaminergic, histaminergic, orexinergic, noradrenergic) rather than pure monoamine reuptake inhibition. This multi-circuit engagement may explain both its clinical distinctness from amphetamines and the difficulty in pinning down a single mechanism.